Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Learn why index funds are a popular choice for retirement, offering broad market exposure, low fees, and straightforward, scalable strategy.
24,587 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Trump backs down on the controversial anti-weaponization fund, clearing the path for immigration enforcement funding ...
International stocks winning again is moving from headlines to portfolio reality as ex-US ETFs post strong gains and ...
Veteran investors known for patient, low-turnover strategies are guiding portfolios as markets drift higher. This pie...
A former minutes correspondent doesn't express confidence in the long-term future of 60 Minutes as advertisers shift ...
As SpaceX eyes a potential mega-IPO, a veteran market strategist says the issue could force a broad rotation, unlocki...
As of June 26, 2026, the Invesco KBW High Dividend Yield Financial ETF faces renewed scrutiny over whether its double...
As July opens, traders are eyeing a quiet market mover. This unheralded sector sure has a track record of supporting ...
A major hedge fund just sold its entire Abercrombie & Fitch stake. Here’s what that means for investors, how to inter...
Kettle Hill Capital Management disclosed a new stake in RH, loading about 161,122 shares worth roughly $28.9 million....
The latest Labor Department data show wage gains outpacing inflation, helping households stretch every pay period as ...
A veteran contrarian warns that the AI-driven Nasdaq rally resembles the dot-com era. Bitcoin sits at a crossroads as...